Company Reports

Recent Updates

All Reports

Company Report

After selling DaVita Medical Group in 2019, DaVita focuses on providing services to end-stage renal disease, or ESRD, patients primarily in the United States, although its international footprint has been expanding organically and through acquisitions. Over several decades, DaVita has built one of the largest networks of dialysis clinics in the US, and although covid-related mortality and labor pressures cut into its profits in recent years, we see brighter days ahead for the firm, despite long-term potential challenges emerging related to the expansion of obesity drugs.
Stock Analyst Note

After hours on Oct. 29, DaVita reported third-quarter results showing 5% revenue growth and a 5% decline in adjusted EPS to $3.82, still above FactSet’s consensus of $3.52. Management also raised the low end of its 2026 profit outlook but did not change its cash flow goal.
Company Report

After selling DaVita Medical Group in 2019, DaVita focuses on providing services to end-stage renal disease, or ESRD, patients primarily in the United States, although its international footprint is expanding organically and through acquisitions. Over several decades, DaVita has built one of the largest networks of dialysis clinics in the US, and although covid-related mortality and labor pressures cut into its profits in recent years, we see brighter days ahead for the firm, despite long-term potential challenges emerging related to the expansion of obesity drugs.
Stock Analyst Note

DaVita reported second-quarter results with 5% revenue growth, 5% adjusted operating profit growth, and 36% adjusted EPS growth, with significant debt-funded share repurchase activity. Management also maintained the 2026 outlook, including adjusted EPS of $14.10-$15.20.
Company Report

After selling DaVita Medical Group in 2019, DaVita focuses on providing services to end-stage renal disease, or ESRD, patients primarily in the United States, although its international footprint is expanding organically and through acquisitions. Over several decades, DaVita has built one of the largest networks of dialysis clinics in the US, and although covid-related mortality and labor pressures cut into its profits in recent years, we see brighter days ahead for the firm, despite long-term potential challenges emerging related to the expansion of obesity drugs.
Company Report

After selling DaVita Medical Group in 2019, DaVita focuses on providing services to end-stage renal disease, or ESRD, patients primarily in the United States, although its international footprint is expanding organically and through acquisitions. Over several decades, DaVita has built the largest network of dialysis clinics in the US, and although covid-19-related mortality and labor pressures cut into its profits in recent years, we see brighter days ahead for the firm, despite long-term potential challenges emerging related to the expansion of obesity drugs.
Stock Analyst Note

In the quarter, DaVita showed revenue growth of 5%, but adjusted earnings per share declined 12% on elevated costs per patient, including pharmaceutical costs. With the help of share repurchases and other controls, DaVita kept its outlook for adjusted EPS and free cash flow intact for the full year.
Company Report

After selling DaVita Medical Group in 2019, DaVita has focused on providing services to end-stage renal disease, or ESRD, patients primarily in the United States, although its international footprint is expanding organically and through acquisitions. Over several decades, DaVita has built the largest network of dialysis clinics in the US, and although covid-19-related mortality and labor pressures cut into its profits in recent years, we see brighter days ahead for the firm, despite long-term potential challenges emerging on the obesity drug front.
Company Report

After selling DaVita Medical Group in 2019, DaVita has focused on providing services to end-stage renal disease, or ESRD, patients primarily in the United States, although its international footprint is expanding organically and through acquisitions. Over several decades, DaVita has built the largest network of dialysis clinics in the US, and although covid-19-related mortality and labor pressures cut into its profits in recent years, we see brighter days ahead for the firm despite some challenges emerging on the obesity drug front.
Stock Analyst Note

Higher rates on new debt pressured narrow-moat DaVita's third-quarter results, but DaVita maintained its 2024 operating outlook and gave an initial view for 2025 that included adjusted operating income growth returning to prepandemic norms of 3% to 7%. Our near-term expectations appear roughly in line with that view, and we are keeping our $134 fair value estimate intact. While DaVita shares still appear overvalued to us, shares are retreating closer toward our fair value after this call.
Company Report

After selling DaVita Medical Group in 2019, DaVita has focused on providing services to end-stage renal disease, or ESRD, patients primarily in the United States, although its international footprint is expanding organically and through acquisitions. Over several decades, DaVita has built the largest network of dialysis clinics in the US, and although covid-19-related mortality and labor pressures cut into its profits in recent years, we see brighter days ahead for the firm despite some challenges emerging on the obesity drug front.

Sponsor Center